OTTAWA, Ontario (PRWEB)March 26, 2018
Orion Biotechnology Canada Ltd., a developer of novel medical treatments, today announced that Mark Groper has joined as the company’s new President, CEO and a member of the board of directors. Rudolf Bom, who served as the company’s founder and CEO since 2011, will assume the position of Chairman of the Board.
As a health industry expert, Mr. Groper has been an important advisor and consultant to Orion on the development of the company and its business strategy. “Over the past years we have benefited greatly from Mr. Groper’s guidance and entrepreneurial expertise. I am delighted to have him renew and deepen his commitment to the organization,” said Rudolf Bom. “We feel very fortunate to have attracted someone of Mark’s reputation and caliber as the new leader of Orion Biotechnology. He brings a proven track record of success and world class business acumen to take Orion into its next phase of growth.”
Mr. Groper is a veteran business executive with more than 30 years’ experience in the health industry including the health care, pharmaceutical and biotechnology sectors. He has previously held senior executive positions with Accenture, Emergis, Telus Health and DINMAR – a health care company he founded, operated and grew to become a highly success international business. In addition to his executive leadership experience in both private and public-sector organizations, Mr. Groper brings a wealth of international product development experience having served in North America, Europe and the Asia-Pacific.
Commenting on his appointment, Mr. Groper said, “I am delighted to be joining Orion at such an exciting time in its development. The company’s current pipeline of products has tremendous potential to radically improve the health of the global population. In addition, the combination of the company’s world class scientific talent and established relationships with leading research institutions around the globe have created a powerful engine for the rapid identification and development of novel treatments for emerging health issues.”
Dr. Ian McGowan, Orion’s Chief Scientific Officer added, “It takes different disciplines to successfully bring a new treatment from concept and initial formulation through to a proven market product. It takes strong entrepreneurial and business leadership throughout the development life cycle that many biotechnology companies are lacking. Our clinical team is ecstatic to have Mark lead the company – an individual that provides proven executive leadership, strong governance, sound judgement and integrity.”
About Orion Biotechnology Canada, Ltd.
Orion Biotechnology Canada Ltd, is a privately held pharmaceutical company founded on the vision of radically improving the health of the global population through successful treatment and prevention of the most serious chronic illnesses and life-threatening diseases. Since 2011, Orion has been developing a robust pipeline of potential products based on novel formulations discovered in different parts of the world. Our close ties to diverse institutions and experts around the globe continue to stimulate the rapid discovery of promising new treatments. With operations in North America, Europe and Asia, Orion brings together innovative technologies from some of the world’s leading research institutions such as the Mintaka Research Foundation and the Center for Public Health Research at Nanjing University. Learn more at https://www.orionbiotechnology.com.
This press release contains forward-looking information, which reflects Orion’s current expectations regarding future events. Forward-looking information is based on a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond Orion’s control, that could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking information. These forward-looking statements are made as of the date of this press release and, except as expressly required by applicable law, Orion assumes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.